Literature DB >> 19587051

Ebolavirus glycoprotein GP masks both its own epitopes and the presence of cellular surface proteins.

Olivier Reynard1, Malgorzata Borowiak, Valentina A Volchkova, Sebastien Delpeut, Mathieu Mateo, Viktor E Volchkov.   

Abstract

Ebolavirus (EBOV) is the etiological agent of a severe hemorrhagic fever with a high mortality rate. The spike glycoprotein (GP) is believed to be one of the major determinants of virus pathogenicity. In this study, we demonstrated the molecular mechanism responsible for the downregulation of surface markers caused by EBOV GP expression. We showed that expression of mature GP on the plasma membrane results in the masking of cellular surface proteins, including major histocompatibility complex class I. Overexpression of GP also results in the masking of certain antigenic epitopes on GP itself, causing an illusory effect of disappearance from the plasma membrane.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19587051      PMCID: PMC2738224          DOI: 10.1128/JVI.00784-09

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  24 in total

1.  Recovery of infectious Ebola virus from complementary DNA: RNA editing of the GP gene and viral cytotoxicity.

Authors:  V E Volchkov; V A Volchkova; E Muhlberger; L V Kolesnikova; M Weik; O Dolnik; H D Klenk
Journal:  Science       Date:  2001-02-01       Impact factor: 47.728

2.  Downregulation of beta1 integrins by Ebola virus glycoprotein: implication for virus entry.

Authors:  A Takada; S Watanabe; H Ito; K Okazaki; H Kida; Y Kawaoka
Journal:  Virology       Date:  2000-12-05       Impact factor: 3.616

Review 3.  Biosynthesis and role of filoviral glycoproteins.

Authors:  Heinz Feldmann; Viktor E Volchkov; Valentina A Volchkova; Ute Ströher; Hans-Dieter Klenk
Journal:  J Gen Virol       Date:  2001-12       Impact factor: 3.891

4.  Ebola virus glycoproteins induce global surface protein down-modulation and loss of cell adherence.

Authors:  Graham Simmons; Rouven J Wool-Lewis; Frédéric Baribaud; Robert C Netter; Paul Bates
Journal:  J Virol       Date:  2002-03       Impact factor: 5.103

5.  Identification of the Ebola virus glycoprotein as the main viral determinant of vascular cell cytotoxicity and injury.

Authors:  Z Y Yang; H J Duckers; N J Sullivan; A Sanchez; E G Nabel; G J Nabel
Journal:  Nat Med       Date:  2000-08       Impact factor: 53.440

6.  The matrix protein of Marburg virus is transported to the plasma membrane along cellular membranes: exploiting the retrograde late endosomal pathway.

Authors:  Larissa Kolesnikova; Sandra Bamberg; Beate Berghöfer; Stephan Becker
Journal:  J Virol       Date:  2004-03       Impact factor: 5.103

7.  Ebola virus glycoprotein: proteolytic processing, acylation, cell tropism, and detection of neutralizing antibodies.

Authors:  H Ito; S Watanabe; A Takada; Y Kawaoka
Journal:  J Virol       Date:  2001-02       Impact factor: 5.103

8.  Further studies on the relationship between large glycoprotein molecules and allotransplantability in the TA3 tumor of the mouse: studies on segregating TA3-HA hybrids.

Authors:  J F Codington; G Klein; A G Cooper; N Lee; M C Brown; R W Jeanloz
Journal:  J Natl Cancer Inst       Date:  1978-04       Impact factor: 13.506

9.  Ectodomain shedding of the glycoprotein GP of Ebola virus.

Authors:  Olga Dolnik; Valentina Volchkova; Wolfgang Garten; Caroline Carbonnelle; Stephan Becker; Jörg Kahnt; Ute Ströher; Hans-Dieter Klenk; Viktor Volchkov
Journal:  EMBO J       Date:  2004-04-22       Impact factor: 11.598

10.  Requirements for cell rounding and surface protein down-regulation by Ebola virus glycoprotein.

Authors:  Joseph R Francica; Meghan K Matukonis; Paul Bates
Journal:  Virology       Date:  2008-11-14       Impact factor: 3.616

View more
  46 in total

1.  Less is more: Ebola virus surface glycoprotein expression levels regulate virus production and infectivity.

Authors:  Gopi S Mohan; Ling Ye; Wenfang Li; Ana Monteiro; Xiaoqian Lin; Bishu Sapkota; Brian P Pollack; Richard W Compans; Chinglai Yang
Journal:  J Virol       Date:  2014-11-12       Impact factor: 5.103

2.  Newcastle disease virus-vectored rabies vaccine is safe, highly immunogenic, and provides long-lasting protection in dogs and cats.

Authors:  Jinying Ge; Xijun Wang; Lihong Tao; Zhiyuan Wen; Na Feng; Songtao Yang; Xianzhu Xia; Chinglai Yang; Hualan Chen; Zhigao Bu
Journal:  J Virol       Date:  2011-06-01       Impact factor: 5.103

3.  Structure of an antibody in complex with its mucin domain linear epitope that is protective against Ebola virus.

Authors:  Daniel Olal; Ana I Kuehne; Shridhar Bale; Peter Halfmann; Takao Hashiguchi; Marnie L Fusco; Jeffrey E Lee; Liam B King; Yoshihiro Kawaoka; John M Dye; Erica Ollmann Saphire
Journal:  J Virol       Date:  2011-12-14       Impact factor: 5.103

4.  Efficacy of Ebola Glycoprotein-Specific Equine Polyclonal Antibody Product Against Lethal Ebola Virus Infection in Guinea Pigs.

Authors:  Mable Chan; Frederick W Holtsberg; Hong Vu; Katie A Howell; Anders Leung; Evelyn Van der Hart; Paul H Walz; M Javad Aman; Shantha Kodihalli; Darwyn Kobasa
Journal:  J Infect Dis       Date:  2018-11-22       Impact factor: 5.226

5.  The cytoplasmic domain of Marburg virus GP modulates early steps of viral infection.

Authors:  Eva Mittler; Larissa Kolesnikova; Bettina Hartlieb; Robert Davey; Stephan Becker
Journal:  J Virol       Date:  2011-06-15       Impact factor: 5.103

Review 6.  Filovirus entry into cells - new insights.

Authors:  Emily Happy Miller; Kartik Chandran
Journal:  Curr Opin Virol       Date:  2012-03-23       Impact factor: 7.090

7.  Impact of Ebola mucin-like domain on antiglycoprotein antibody responses induced by Ebola virus-like particles.

Authors:  Osvaldo Martinez; Lee Tantral; Nirupama Mulherkar; Kartik Chandran; Christopher F Basler
Journal:  J Infect Dis       Date:  2011-11       Impact factor: 5.226

Review 8.  Hunting Viral Receptors Using Haploid Cells.

Authors:  Sirika Pillay; Jan E Carette
Journal:  Annu Rev Virol       Date:  2015-07-02       Impact factor: 10.431

Review 9.  Anti-Ebola therapies based on monoclonal antibodies: current state and challenges ahead.

Authors:  Everardo González-González; Mario Moisés Alvarez; Alan Roberto Márquez-Ipiña; Grissel Trujillo-de Santiago; Luis Mario Rodríguez-Martínez; Nasim Annabi; Ali Khademhosseini
Journal:  Crit Rev Biotechnol       Date:  2015-11-26       Impact factor: 8.429

10.  Inhibition of Ebola virus glycoprotein-mediated cytotoxicity by targeting its transmembrane domain and cholesterol.

Authors:  Moritz Hacke; Patrik Björkholm; Andrea Hellwig; Patricia Himmels; Carmen Ruiz de Almodóvar; Britta Brügger; Felix Wieland; Andreas M Ernst
Journal:  Nat Commun       Date:  2015-07-09       Impact factor: 14.919

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.